In­tra-Cel­lu­lar Ther­a­pies gets a boost on PhI­II de­pres­sion drug da­ta

Biotech In­tra-Cel­lu­lar Ther­a­pies tout­ing new da­ta Tues­day for its drug de­signed to treat ma­jor de­pres­sive dis­or­der.

The biotech shared re­sults from its Study 403 in­ves­ti­gat­ing lu­mate­per­one, or Caply­ta, as a monother­a­py to treat ma­jor de­pres­sive episodes. The study looked at ma­jor de­pres­sive dis­or­der (MDD) and bipo­lar de­pres­sion with “mixed fea­tures.” The tri­al had three pop­u­la­tions: par­tic­i­pants with both MDD and bipo­lar de­pres­sion, pa­tients with on­ly MDD and pa­tients with on­ly bipo­lar de­pres­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER